# DESCRIPTION

## FIELD OF THE INVENTION

- define invention scope

## BACKGROUND

- discuss PSMA and CD3

## BRIEF SUMMARY OF THE INVENTION

- introduce anti-PSMA antibodies
- describe bispecific antibodies
- list exemplary anti-PSMA antibodies
- define antibody components
- provide nucleic acid molecules encoding antibodies
- provide nucleic acid molecules encoding LCDR2 and HCVR amino acid sequences
- provide recombinant expression vectors and host cells
- provide anti-PSMA antibodies with modified glycosylation patterns
- provide pharmaceutical compositions and therapeutic methods
- provide isolated antibodies or antigen-binding fragments with specific binding properties
- provide bispecific antigen-binding molecules that bind PSMA and CD3
- provide specific embodiments of bispecific antigen-binding molecules
- define bispecific molecules
- describe CD3 binding domains
- describe PSMA binding domains
- provide exemplary bispecific molecules
- describe heavy and light chain CDRs
- provide additional bispecific molecule embodiments
- define bispecific antigen-binding molecules
- describe binding properties
- outline pharmaceutical compositions
- describe methods for treating cancer
- provide nucleic acid molecules and expression vectors
- outline therapeutic methods and uses

## DETAILED DESCRIPTION

- define terms and concepts

### Definitions

- define CD3
- define antibody that binds CD3
- define PSMA
- define antibody that binds PSMA
- define antigen-binding molecule
- define antibody
- define antigen-binding fragment
- describe configurations of variable and constant domains
- describe multispecific antigen-binding fragments
- define complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity
- define human antibody
- define isolated antibody

### Germline Mutations

- define germline mutations
- describe antibodies with germline mutations
- summarize properties of antibodies with germline mutations

### Binding Properties of the Antibodies

- define binding and affinity
- describe measurement of binding affinity

### Bispecific Antigen-Binding Molecules

- define bispecific antigen-binding molecules
- describe structure of bispecific antibodies
- explain multimerizing domains and Fc fragments
- discuss various bispecific formats and technologies
- describe modifications to Fc domains and their effects
- provide examples of chimeric Fc domains and heavy chain constant regions

### Sequence Variants

- define germline mutations
- describe conservative substitutions
- summarize substantial identity
- introduce pH-dependent binding

### Antibodies Comprising Fc Variants

- describe Fc domain mutations

### Biological Characteristics of the Antibodies and Bispecific Antigen-Binding Molecules

- define antibodies and antigen-binding fragments
- describe binding affinity to human PSMA
- describe dissociative half-life of antibodies and antigen-binding fragments
- introduce bispecific antigen-binding molecules
- describe binding characteristics of bispecific antigen-binding molecules
- describe functional characteristics of bispecific antigen-binding molecules
- describe binding affinity to human CD3
- describe functional characteristics of antibodies and antigen-binding fragments
- describe in vivo effects of bispecific antigen-binding molecules

### Epitope Mapping and Related Technologies

- define epitope
- describe epitope mapping techniques
- specify antibodies and bispecific antigen-binding molecules
- determine epitope binding and competition

### Preparation of Antigen-Binding Domains and Construction of Bispecific Molecules

- prepare antigen-binding domains
- construct bispecific antigen-binding molecules
- discuss bispecific antibody formats
- describe VELOCIMUNE technology
- discuss genetically engineered animals
- outline human bispecific antigen-binding molecules
- describe preparation of antigen-binding domains
- describe therapeutic uses of antigen-binding molecules
- describe combination therapies and formulations
- describe administration regimens
- describe diagnostic uses of antibodies
- motivate therapeutic methods
- describe pharmaceutical compositions
- describe treatment of residual cancer

## EXAMPLES

- provide examples of methods and compositions of the invention

### Example 1: Generation of Anti-PSMA Antibodies

- generate anti-PSMA antibodies using genetically modified mice

### Example 2: Heavy and Light Chain Variable Region Amino Acid and Nucleic Acid Sequences of Anti-PSMA Antibodies

- describe sequences of heavy and light chain variable regions of anti-PSMA antibodies

### Example 3: Surface Plasmon Resonance Derived Binding Affinities and Kinetic Constants of Human Monoclonal Anti-PSMA Antibodies

- determine binding affinities and kinetic constants of anti-PSMA antibodies

### Example 4: Generation of Bispecific Antibodies that Bind Prostate-Specific Membrane Antigen (PSMA) and CD3

- generate bispecific antibodies that bind PSMA and CD3

### Example 5: Binding Affinities of Exemplified Bispecific Antibodies as Measured by FACS Analysis

- determine binding affinities of bispecific antibodies to human PSMA and CD3

### Example 6: Binding Affinities of Exemplified Antibodies as Measured by a Surface Plasmon Resonance Binding Assay

- determine binding affinities of bispecific antibodies to soluble CD3 protein

### Example 7: T Cell Activation and Tumor-Specific Cytotoxicity Exhibited by Bispecific Antibodies of the Invention as Measured In Vitro

- assess T cell activation and tumor-specific cytotoxicity of bispecific antibodies

### Example 8: Anti-PSMA/Anti-CD3 Bispecific Antibodies Display Potent Anti-Tumor Efficacy In Vivo

- describe in vivo efficacy studies
- present results of anti-tumor efficacy in various xenograft models
- summarize efficacy and specificity of anti-PSMA/anti-CD3 bispecific antibodies

### Example 9: Generation of Anti-CD3 Antibodies

- generate anti-CD3 antibodies using engineered mouse
- monitor antibody immune response using CD3-specific immunoassay
- harvest and fuse splenocytes with mouse myeloma cells
- screen and select hybridoma cell lines for CD3-specific antibodies
- obtain chimeric and fully human anti-CD3 antibodies
- describe biological properties of generated anti-CD3 antibodies
- reference additional methods for making anti-CD3 antibodies

